Skip to main content
. 2024 Oct 23;11(6):e200328. doi: 10.1212/NXI.0000000000200328

Figure 2. Annualized Relapse Rates (ARRs) Before Pregnancy, During Pregnancy, and in the Postpartum Period for Term/Preterm Pregnancies by Preconception Disease-Modifying Therapy Group.

Figure 2

(A) ARR was plotted for each 3-month interval. (B) ARR was summarized for the 1-year prepregnancy, pregnancy, and 6-month postpartum periods, respectively. Natalizumab (NAT) groups represent either an active (NAT-A) or conservative (NAT-C) strategy of use during and after pregnancy. Low-efficacy group refers to interferon-beta or glatiramer acetate preconception use. Error bars represent 95% confidence intervals. Table represents number of women with time included for each 3-month interval. DMF = dimethyl fumarate; NAT = natalizumab; OCR = ocrelizumab.